About Us
Committed to becoming a global leader in synthetic biology

Corporate Overview

JHM is a business dedicated to the development and commercialization of innovative synthetic biology products and technologies. JHM is committed to advancing the use of innovative recombinant protein drugs in endocrine therapy, neurotherapy, anti-aging skincare, and other next-generation biomedical material applications. Our mission is to provide groundbreaking biopharmaceutical products and treatments to patients worldwide.

Full Market Coverage

JHM focuses on healthcare applications. Our products include JHM01 Human Growth Hormone（under development），JHM02 Long-Acting Recombinant Human Growth Hormone（under development），JHM03 Recombinant Type A Botulinum Toxin（under development），JHM09(Class III Medical Devices)，Recombinant Human Collagen Raw material.

Vertically Integrated Model

Headquartered in Hangzhou, Zhejiang, China, JHM operates two GMP factories — one in Hangzhou and one in Tonghua. The Company excels in all phases of drug development and commercialization, from early-stage drug discovery and process development to clinical trials, manufacturing preparation, and product launch. This vertically integrated model provides a significant competitive advantage, allowing JHM to lead the industry’s rapid progress and innovative transformation.

Market Recognition

Since its establishment, JHM has successfully completed multiple rounds of financing, from Pre-A to B+, demonstrating the capital market’s prominent recognition of the company’s technological strength, product pipeline, and commercial prospects.

Government Endorsement

In 2024, JHM was recognized as a “Specialized and Sophisticated SME in Zhejiang Province.”